LUMEVOQ

PARIS, FRANCE: GenSight Biologics, a biopharma company that develops gene therapies for eye and brain disorders, announced today that it has secured enough cash to operate until mid-February 2024, thanks to cost-cutting measures and ongoing negotiations with some business partners…